N-(ethoxycarbonyl)thiovaleramide | 72139-56-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代酰胺
• 英文名称: N-(ethoxycarbonyl)thiovaleramide
• 英文别名: N-ethoxycarbonyl thiovaleramide；N-(Thiovaleryl)carbaminsaeure-ethylester；ethyl N-pentanethioylcarbamate
• CAS: 72139-56-1
• 化学式: C₈H₁₅NO₂S
• 分子量: 189.279
• InChiKey: YYEKHNBJKUBVCH-UHFFFAOYSA-N

物化性质

• 熔点：
  30-31 °C(Solv: hexane (110-54-3))
• 密度：
  1.064±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  70.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(ethoxycarbonyl)thiovaleramide 在 potassium carbonate 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 30.0h， 生成 5-Butyl-2-phenyl-4-[2'-(2-trityl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one
  参考文献：
  名称：

  Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists

  摘要：

  2,5-Dibutyl-2,4-dihydro-4-[[2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4'-yl]methyl] -3H-1,2,4-triazol-3-one, SC-51316, was synthesized as a potent and orally active angiotensin II (AII) receptor antagonist with a long duration of action. To explore the lipophilic pocket in the AII receptor interacting with the substituent at the 2-position of triazolone-based antagonists, a series of compounds were prepared and evaluated for receptor binding affinity and antagonism of AII-contracted rabbit aortic rings. It has been found that the pocket is very spacious and can accommodate different sizes of lipophilic groups and various functionalities. Acidic groups generally result in a slight decrease in binding affinity. Branched chains are unfavorable. The freedom of rotation around C2-C3 in the flexible side chain is crucial for good binding. The 2-phenylethyl-substituted triazolone analogue exhibits the highest in vitro potency among all compounds that have been synthesized.

  DOI：

  10.1021/jm00067a015
• 作为产物：
  描述：

  正丁基氯化镁 、 异硫氰酰甲酸乙酯 以 四氢呋喃 为溶剂， 以43.2 %的产率得到N-(ethoxycarbonyl)thiovaleramide
  参考文献：
  名称：

  一种血管紧张肽和内皮肽受体拮抗剂及其应用

  摘要：

  本发明属于化学药物技术领域，提供了一种兼为血管紧张肽和内皮肽受体拮抗剂化合物及其制备方法和医药用途。

  公开号：

  CN115745983A

文献信息

• N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders
  申请人：G.D. Searle & Co.

  公开号：US20010020100A1

  公开（公告）日：2001-09-06

  A class of N-substituted-1,2,4-triazolone compounds is described for use in treatment of cardiovascular disorders. Compounds of particular interest are angiotensin II antagonists of the formula 1 wherein R 1 is selected from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, 4-methylbutyl, n-pentyl, neopentyl, phenyl, benzyl, phenethyl, cyclohexyl, cyclohexylmethyl, 1-oxoethyl, 1-oxopropyl, 1-oxobutyl, 1-oxopentyl and hydroxyalkyl; wherein R 2 is selected from ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, 4-methylbutyl, tert-butyl, n-pentyl, neo-pentyl, propylthio and butylthio; wherein each of R 3 through R 11 is hydrido with the proviso that at least one of R 5 and R 9 must be selected from COOH, SH, PO 3 H 2 , SO 3 H, CONHNH 2 , CONHNHSO 2 CF 3 , OH, 2 wherein each of R 42 and R 43 is independently selected from chloro, cyano, nitro, trifluoromethyl, methoxycarbonyl and trifluoromethylsulfonyl. These compounds are particularly useful in treatment or control of hypertension and congestive heart failure.

  描述了一类N-取代-1,2,4-三唑酮化合物，用于治疗心血管疾病。特别感兴趣的化合物是公式1的血管紧张素II拮抗剂，其中R1从甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、4-甲基丁基、正戊基、新戊基、苯基、苄基、苯乙基、环己基、环己基甲基、1-氧乙基、1-氧丙基、1-氧丁基、1-氧戊基和羟基中选择；其中R2从乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、4-甲基丁基、叔丁基、正戊基、新戊基、丙硫基和丁硫基中选择；其中R3至R11中的每一个都是氢，但R5和R9中至少一个必须从COOH、SH、PO3H2、SO3H、CONHNH2、CONHNHSO2CF3、OH中选择；其中R42和R43中的每一个都是独立选择的氯、氰基、硝基、三氟甲基、羟甲酰氧基和三氟甲磺酰基。这些化合物在治疗或控制高血压和充血性心力衰竭方面特别有用。
• Gossauer,A. et al., Liebigs Annalen der Chemie, 1979, p. 1309 - 1321
  作者：Gossauer,A. et al.

  DOI：——

  日期：——
• GOSSAUER A.; ROESSLER F.; ZILCH H., LIEBIGS ANN. CHEM., 1979, NO 9, 1309-1321
  作者：GOSSAUER A.、 ROESSLER F.、 ZILCH H.

  DOI：——

  日期：——
• Synthesis and structure-activity relationships of nonpeptide, potent triazolone-based angiotensin II receptor antagonists
  作者：Horng Chih Huang、David B. Reitz、Timothy S. Chamberlain、Gillian M. Olins、Valerie M. Corpus、Ellen G. McMahon、Maria A. Palomo、John P. Koepke、Glenn J. Smits

  DOI：10.1021/jm00067a015

  日期：1993.7

  2,5-Dibutyl-2,4-dihydro-4-[[2-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4'-yl]methyl] -3H-1,2,4-triazol-3-one, SC-51316, was synthesized as a potent and orally active angiotensin II (AII) receptor antagonist with a long duration of action. To explore the lipophilic pocket in the AII receptor interacting with the substituent at the 2-position of triazolone-based antagonists, a series of compounds were prepared and evaluated for receptor binding affinity and antagonism of AII-contracted rabbit aortic rings. It has been found that the pocket is very spacious and can accommodate different sizes of lipophilic groups and various functionalities. Acidic groups generally result in a slight decrease in binding affinity. Branched chains are unfavorable. The freedom of rotation around C2-C3 in the flexible side chain is crucial for good binding. The 2-phenylethyl-substituted triazolone analogue exhibits the highest in vitro potency among all compounds that have been synthesized.
• 一种血管紧张肽和内皮肽受体拮抗剂及其应用
  申请人：深圳信立泰药业股份有限公司

  公开号：CN115745983A

  公开（公告）日：2023-03-07

  本发明属于化学药物技术领域，提供了一种兼为血管紧张肽和内皮肽受体拮抗剂化合物及其制备方法和医药用途。